Navigation Links
Research: Improving treatment of patients with heart attack
Date:6/25/2009

This release is available in French.

Montreal, June 25th 2009 When faced with patients suffering a heart attack, doctors have two choices: inject them with medication to dissolve the blood clot (fibrinolytic therapy) or insert a small balloon to open the blocked artery (primary percutaneous coronary intervention (PCI)). Guidelines for treating heart attacks are generally based on clinical trials that do not take "real-life" conditions into account. The latest study by Dr. Thao Huynh of the Research Institute of the MUHC analyses these gaps and provides potential solutions to improve treatment of heart attack. Her article was published in the June 23rd issue of Circulation.

In this study, Dr. Huynh compares the results of 23 randomized controlled trials conducted under controlled experimental conditions, with the results of 32 observational studies reporting on the treatment of patients with heart attacks in routine clinical conditions.

Both types of studies show the superiority of PCI over fibrinolytic therapy in reducing mortality and the risk of further episodes of cardiac arrest and stroke over the short term. However, the advantage of PCI is even more apparent in randomized controlled trials where delays in providing primary PCI are shorter than in routine clinical conditions.

"This study indeed demonstrates that we have to work to reduce these delays if we are to maximize the effectiveness of PCI," explained Dr. Huynh. "When it comes to treating heart attack, reducing delays in providing treatment is the number one priority. It is also essential that patients with symptoms of heart attack seek prompt medical attention. Delays by patients to seek medical attention may further increase delays to treatment of heart attack. "

Analysis of randomized controlled trials shows that primary PCI also reduces long-term mortality and repeat heart attack. However, this long-term benefit of primary PCI is not observed in observational studies where patients receive treatment within routine clinical conditions.

"The benefit of primary PCI can be lost over the long term if patients are not receiving optimal medical therapy after discharge from hospital. These medications are essential to prevent repeat heart attack." warned Dr. Huynh.


'/>"/>

Contact: Isabelle Kling
isabelle.klign@muhc.mcgill.ca
514-843-1560
McGill University Health Centre
Source:Eurekalert

Related medicine news :

1. Manhattan Research: Physician New Media Adoption in Emerging Pharma Markets - Webcast April 3
2. Radiological Society of North America research: Cancer risk from cardiac CT overstated
3. New Research: Americans Underestimate Dangers of Sudden Cardiac Arrest
4. Conning Research: Long Term Care Insurance Industry Continues to Search for Broader Market
5. New EBRI/Commonwealth Fund Research: Enrollment in Consumer-Driven Plans Remains Low, Survey Shows
6. Experimental Biology 2008 Todays Research: Tomorrows Health, April 5-9
7. Manhattan Research: ePharma Consumer(R) Research and Advisory Service Now Available
8. Broad Coalition Says Consumer Role Is Key to Improving Health and Health Care
9. Beth Israel Medical Center Receives Major American Cancer Society Grant Toward Improving Pain Management in Chinese Cancer Patients
10. United Spinal Associations 2009 Independence Expo Aug. 7th-8th In Orlando: Improving Life for the Disabled and the Aging
11. United Spinal Association Presents The 2009 Independence Expo: Improving Life for the Disabled and the Aging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... York, NY (PRWEB) , ... January 17, 2017 , ... ... grand opening of a new showroom at South Dixie Hwy in Miami, FL. , ... Officer at Gym Source. “The new innovative in-store concept is designed to give clients ...
(Date:1/17/2017)... ... ... For breast cancer clinicians and researchers who were unable to attend the ... review and analysis of its highlights, a novel half-day, complimentary meeting—the 14th Annual Best ... February 4, 2017 in Chicago. Chaired by Kathy S. Albain, MD, FACP, FASCO from ...
(Date:1/17/2017)... ... January 17, 2017 , ... Healthful Balance announces ... company, owned and operated by Ed Stroup, was created to offer the highest ... highest level of customer service. Healthful Balance products can be purchased online through ...
(Date:1/17/2017)... Petersburg, Florida (PRWEB) , ... January 17, 2017 , ... ... the Producers of AsSeenOnTV.pro will be featuring DRTV campaigns regarding the topic of Beauty ... to become a better version of themselves. What better way to commit to these ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... century approach to infusing high speed technology into the fabric of an entire ... the advancement of healthcare and wellness in a yet-to-be-named, health focused campus. Leading ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... LONDON , January 18, 2017 ... community to share research resources, has opened its first North ... . ... This marks an expansion for Ximbio following its launch in ... Cancer Research Technology (CRT), the commercialization arm of the foundation ...
(Date:1/18/2017)... 2017 After the recent election cycle, ... of cannabis both for medical and recreational purposes are shifting. ... to the use of cannabis, but the focus is coming ... Market Research, the North American legal cannabis market posted $6.7 ... year. The research projects sales will grow at a compound ...
(Date:1/18/2017)... , Jan. 18, 2017  Astellas Pharma Inc. ... ) today announced its participation in Access Accelerated, ... non-communicable disease (NCD) prevention, diagnostics and treatment in ... other leading pharmaceutical companies and in collaboration with ... International Cancer Control (UICC), Astellas will work towards ...
Breaking Medicine Technology: